8M Float 8% Short $386 M market cap Offering complete Feb 12 Looks like AUTL may be breaking out of it's downtrend soon. I picked up a position on Feb 12. Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Autolus Therapeutics today and set a price target of $18.00. The company’s shares closed last Friday at $7.29. According to TipRanks.com,...
I am waiting. Week must close above the black line(month resistance) Wait for a nice entry on the day!
AUTL: Autolus Therapeutics plc 2019-11-05 09:10:33 Autolus Therapeutics Receives FDA Orphan Drug Designation for AUTO1 for Treatment of Acute Lymphoblastic Leukemia